Grit Andersen

463 total citations · 1 hit paper
21 papers, 335 citations indexed

About

Grit Andersen is a scholar working on Endocrinology, Diabetes and Metabolism, Surgery and Molecular Biology. According to data from OpenAlex, Grit Andersen has authored 21 papers receiving a total of 335 indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Endocrinology, Diabetes and Metabolism, 8 papers in Surgery and 5 papers in Molecular Biology. Recurrent topics in Grit Andersen's work include Diabetes Management and Research (13 papers), Diabetes Treatment and Management (11 papers) and Pancreatic function and diabetes (7 papers). Grit Andersen is often cited by papers focused on Diabetes Management and Research (13 papers), Diabetes Treatment and Management (11 papers) and Pancreatic function and diabetes (7 papers). Grit Andersen collaborates with scholars based in Germany, United States and Denmark. Grit Andersen's co-authors include Leona Plum‐Mörschel, Paul Hockings, Anni Morsing, Anne Flint, Rohit Loomba, Thomas J. Vogl, L. E. B. Johansson, Tim Heise, Frederick M. Robbins and J. Hans DeVries and has published in prestigious journals such as Diabetes, Toxicology and Applied Pharmacology and Clinical Pharmacokinetics.

In The Last Decade

Grit Andersen

20 papers receiving 326 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Randomised clinical trial: semaglutide versus placebo reduced liver steatosis but not liver stiffness in subjects with non‐alcoholic fatty liver disease assessed by magnetic resonance imaging

2021 146 citations Anne Flint, Grit Andersen et al. Alimentary Pharmacology & Therapeutics profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Grit Andersen Germany	8	227	131	115	75	51	21	335
Lilia M. Jiménez-Ceja Mexico	9	145 0.6×	116 0.9×	38 0.3×	99 1.3×	41 0.8×	13	299
A J Scheen Belgium	7	179 0.8×	86 0.7×	60 0.5×	150 2.0×	58 1.1×	22	351
Johan Vessby Sweden	9	101 0.4×	59 0.5×	128 1.1×	40 0.5×	49 1.0×	22	308
Yukari Fujita Japan	13	180 0.8×	219 1.7×	72 0.6×	66 0.9×	105 2.1×	36	412
Nobuyuki Ogata Japan	10	263 1.2×	96 0.7×	61 0.5×	168 2.2×	62 1.2×	19	448
Emilie Dorchies France	8	76 0.3×	205 1.6×	200 1.7×	239 3.2×	26 0.5×	9	558
F. Samuel van Nierop Netherlands	8	69 0.3×	90 0.7×	148 1.3×	103 1.4×	10 0.2×	10	357
Yujuan Fan China	10	47 0.2×	44 0.3×	77 0.7×	59 0.8×	23 0.5×	23	237
Kiyofumi Honda Japan	7	194 0.9×	112 0.9×	39 0.3×	176 2.3×	29 0.6×	10	324
Ramchandra Ranvir India	8	129 0.6×	77 0.6×	221 1.9×	156 2.1×	10 0.2×	18	388

Countries citing papers authored by Grit Andersen

Since Specialization

Citations

This map shows the geographic impact of Grit Andersen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Grit Andersen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Grit Andersen more than expected).

Fields of papers citing papers by Grit Andersen

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Grit Andersen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Grit Andersen. The network helps show where Grit Andersen may publish in the future.

Co-authorship network of co-authors of Grit Andersen

This figure shows the co-authorship network connecting the top 25 collaborators of Grit Andersen. A scholar is included among the top collaborators of Grit Andersen based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Grit Andersen. Grit Andersen is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Heise, Tim, Grit Andersen, Edward Pratt, et al.. (2024). Frequency and Severity of Hypoglycemia Under Conditions of Increased Hypoglycemic Risk with Insulin Efsitora Alfa Versus Insulin Glargine Treatment in Participants with Type 2 Diabetes. Diabetes Therapy. 15(8). 1785–1797. 4 indexed citations

Andersen, Grit, et al.. (2024). ADO09, a co‐formulation of pramlintide and insulin A21G, lowers body weight versus insulin lispro in type 1 diabetes. Diabetes Obesity and Metabolism. 26(10). 4639–4645. 1 indexed citations

Andersen, Grit, et al.. (2024). 818-P: Effects of Insulin Efsitora Alfa (Efsitora) on Frequency and Severity of Hypoglycemia (Hypo) Under Conditions of Increased Hypo Risk Compared with Glargine in Type 2 Diabetes (T2D). Diabetes. 73(Supplement_1). 1 indexed citations

Andersen, Grit, et al.. (2023). Pharmacokinetic and pharmacodynamic equivalence of Biocon's biosimilar insulin N with US ‐licensed Humulin® N formulation in healthy subjects: Results from the RHINE ‐2 (Recombinant Human INsulin Equivalence‐2) study. Diabetes Obesity and Metabolism. 25(6). 1485–1494. 1 indexed citations

Chen, Wei, Jia Lu, Leona Plum‐Mörschel, et al.. (2023). Pharmacokinetic and pharmacodynamic bioequivalence of Gan & Lee insulin analogues aspart (rapilin®), lispro (prandilin®) and glargine (basalin®) with EU ‐ und US‐sourced reference insulins. Diabetes Obesity and Metabolism. 25(12). 3817–3825. 3 indexed citations

Andersen, Grit, et al.. (2023). A co‐formulation of pramlintide and insulin A21G ( ADO09 ) improves postprandial glucose and short‐term control of mean glucose, time in range, and body weight versus insulin aspart in adults with type 1 diabetes. Diabetes Obesity and Metabolism. 25(5). 1241–1248. 5 indexed citations

Flint, Anne, Grit Andersen, Paul Hockings, et al.. (2021). Randomised clinical trial: semaglutide versus placebo reduced liver steatosis but not liver stiffness in subjects with non‐alcoholic fatty liver disease assessed by magnetic resonance imaging. Alimentary Pharmacology & Therapeutics. 54(9). 1150–1161. 146 indexed citations breakdown →

Andersen, Grit, et al.. (2021). 197-OR: ADO09, a Coformulation of Insulin A21G and Pramlintide (Pram), Improves Blood Glucose Control and Reduces Body Weight in Subjects with T1D. Diabetes. 70(Supplement_1). 1 indexed citations

Leohr, Jennifer, Mary Anne Dellva, David E. Coutant, et al.. (2020). Pharmacokinetics and Glucodynamics of Ultra Rapid Lispro (URLi) versus Humalog® (Lispro) in Patients with Type 2 Diabetes Mellitus: A Phase I Randomised, Crossover Study. Clinical Pharmacokinetics. 59(12). 1601–1610. 26 indexed citations

10.

Andersen, Grit, et al.. (2020). 112-LB: ADO09, a Coformulation of Pramlintide (PRAM) and Insulin A21G, Improves Postprandial Glucose vs. Novolog in Type 1 Diabetes (T1D). Diabetes. 69(Supplement_1). 1 indexed citations

11.

Andersen, Grit, et al.. (2020). Clinical Characteristics of a Non-Alcoholic Fatty Liver Disease Population Across the Fibrosis Spectrum Measured by Magnetic Resonance Elastography: Analysis of Screening Data. Advances in Therapy. 37(12). 4866–4876. 4 indexed citations

12.

Andersen, Grit, et al.. (2020). ADO09, a co‐formulation of the amylin analogue pramlintide and the insulin analogue A21G, lowers postprandial blood glucose versus insulin lispro in type 1 diabetes. Diabetes Obesity and Metabolism. 23(4). 961–970. 22 indexed citations

13.

Andersen, Grit, et al.. (2019). 150-OR: BioChaperone Pramlintide Insulin (BCPramIns), a New Co-Formulation of Pramlintide (PRAM) and Human Insulin (INS), Improves Postprandial Blood Glucose (BG) vs. Both Separate Injections of PRAM+INS and Insulin Lispro (LIS) in Subjects with T1D. Diabetes. 68(Supplement_1). 3 indexed citations

14.

Moschetti, Viktoria, Maria Kim, Michael Sand, et al.. (2018). The safety, tolerability and pharmacokinetics of BI 409306, a novel and potent PDE9 inhibitor: Overview of three Phase I randomised trials in healthy volunteers. European Neuropsychopharmacology. 28(5). 643–655. 10 indexed citations

15.

Andersen, Grit, et al.. (2018). Ultra‐rapid BioChaperone Lispro improves postprandial blood glucose excursions vs insulin lispro in a 14‐day crossover treatment study in people with type 1 diabetes. Diabetes Obesity and Metabolism. 20(11). 2627–2632. 32 indexed citations

16.

Plum‐Mörschel, Leona, et al.. (2018). BioChaperone 222 (BC222), the New Excipient Enabling the Ultra-rapid BioChaperone Lispro (BCLIS) Formulation, Is Completely Absorbed and Rapidly Excreted after Subcutaneous (s.c.) Injection. Diabetes. 67(Supplement_1). 2 indexed citations

17.

Först, Thomas, Grit Andersen, Annelie Fischer, et al.. (2016). Effects on α‐ and β‐cell function of sequentially adding empagliflozin and linagliptin to therapy in people with type 2 diabetes previously receiving metformin: A n exploratory mechanistic study. Diabetes Obesity and Metabolism. 19(4). 489–495. 13 indexed citations

18.

Li, Zhaoyang, Marjie Hard, Grit Andersen, et al.. (2014). Pharmacokinetics, safety and tolerability of mipomersen in healthy Japanese volunteers and comparison with Western subjects. International Journal of Clinical Pharmacology and Therapeutics. 52(4). 314–320. 5 indexed citations

19.

Andersen, Grit, et al.. (1963). The utilization of Schardinger dextrins by the rat. Toxicology and Applied Pharmacology. 5(2). 257–266. 44 indexed citations

20.

Long, C.L., et al.. (1960). The suitability of β-d-glucose pentaacetate for food use. Toxicology and Applied Pharmacology. 2(3). 281–294. 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact